Pear Therapeutics Seeks Approval for Rx Digital Therapeutic to Treat Insomnia, Depression

July 22, 2019

Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression. Read More >>


A national membership association that provides education and advocacy for those in the behavioral health and addiction treatment industries.

We are the leading and unifying voice of addiction-focused treatment programs.

Join Now

Contact Us

Monday - Friday
8:30 am - 4:30 pm Pacific
(closed major holidays)